Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

s target of p<0.05), as previously reported. This was the second primary endpoint.

Implications of these additional data

The significantly reduced sedation seen with M6G provides additional support to our view that M6G is equivalent to morphine in controlling pain but has a superior side-effect profile. This should give clinicians more confidence that patients are less likely to experience sedation with M6G. Sedation is one of the side effects of most concern associated with agents like morphine, along with respiratory depression.

The additional analysis announced today will be used to improve further the designs of the planned US Phase III clinical studies by targeting higher risk patient groups and surgical procedures where the clinical benefits from M6G will be maximised.

Neil Clark, Chief Executive of CeNeS, commented: "This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery - an additional growing market to the current focus on hospital based post-operative pain.

"It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/15/2014)... N.Y. , Dec. 15, 2014 As ... SPL (Structured Product Labeling) markup language standard, content teams ... understanding and skills to work with the standard. Starting ... series of three webinars on the benefits and the ... one-hour webinars will be facilitated by Howard Shatz ...
(Date:12/14/2014)... GREENVILLE, S.C. , Dec. 14, 2014  ChartSpan, ... become the most downloaded iPhone and iPad medical app ... Photo - http://photos.prnewswire.com/prnh/20141214/164317 ... with the ability to request, manage and send electronic ... of innovative entrepreneurs who grew tired of waiting for ...
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... Sept. 22 AstraZeneca today,announced that the United ... additional six-month period of exclusivity to market CASODEX(R),(bicalutamide) ... 1, 2009. AstraZeneca has been working with the ... of CASODEX in a pediatric,setting but will not ...
... a biotech company,focused on developing novel therapeutics for ... commercial and manufacturing expertise to,the Company,s senior management ... clinical trials of ENB-0040 for the treatment of,hypophosphatasia., ... Enobia,s Vice President, Chief,Commercial Officer, and Jayant Aphale, ...
Cached Medicine Technology:AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 2AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 3AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 4Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 2Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 3
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), ... a new study providing evidence on the impact of ... children. , Sufficient enough evidence already exists showing a ... juice drinks, with the onset of tooth decay. One ... listed as 100% fruit juice, meaning it is completely ...
(Date:12/15/2014)... a leading mobile app development company , custom ... which allows users to keep track of wines they ... right wine. At the center of WineMatch is ... wine information. All this information is assembled to help ... are close counterparts to one another are called Matches. ...
(Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... traditional Indian medicine, a four-year degree course in Ayurveda ... for the first time in eastern India//. ... its kind in the country after Gujarat, would be ... in joint venture with West Bengal Health Department under ...
... postmenopausal women has shown that those who indulged in six ... a 3 percent reduction in risk of type 2 diabetes, ... the scientists were not able to place their finger on ... yet they strongly feel that the presence of antioxidants and ...
... Now, Britain's reputed pediatricians, nearly 30 of them have called ... ,Infact they have issued a letter to the public ,that ... triple shots of MMR. ,They have appealed to the ... furore over the supposed link between MMR and autism, especially ...
... a University of Alabama biostatistician has compiled a report on ... assisted in this venture by 19 other scientists in the ... at more than 100 studies on the reasons for obesity ... could be an answer ,* Inadequate sleep: Sleep ...
... in New Zealand. Hence Pharmac decided to fund for the new ... level. // ,It has decided to give Insulin Glargine ... , Murray Dear who is the president for the Diabetes New ... the incidence of diabetes. ,He also said that the ...
... could increase their chances of breast cancer, a study says. ... Agency for Research on Cancer in France analysed 1,600 women. ... susceptibility genes) mutations who had undergone a chest X-ray were ... who had never undergone the procedure. ,Women who ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: